| Autor: |
Olson, R. E., Sielecki, T. M., Wityak, J., Pinto, D. J., Batt, D. G., Frietze, W. E., Liu, J., Tobin, A. E., Orwat, M. J., Meo, S. V. Di, Houghton, G. C., Lalka, G. K., Mousa, S. A., Racanelli, A. L., Hausner, E. A., Kapil, R. P., Rabel, S. R., Thoolen, M. J., Reilly, T. M., Anderson, P. S., Wexler, R. R. |
| Zdroj: |
Journal of Medicinal Chemistry; April 8, 1999, Vol. 42 Issue: 7 p1178-1192, 15p |
| Abstrakt: |
Modification of the α-carbamate substituent of isoxazoline GPIIb/IIIa (αIIbβ3) antagonist DMP 754 (7) led to a series of α-sulfonamide and α-sulfamide diaminopropionate isoxazolinylacetamides which were found to be potent inhibitors of in vitro platelet aggregation. Aryl- and heteroaryl-α-sulfonamide groups, in conjunction with (5R)-isoxazoline (2S)-diaminopropionate stereochemistry, were found to impart a pronounced duration of antiplatelet effect in dogs, potentially due to high affinity for unactivated platelets. Isoxazolylsulfonamide 34b (DMP 802), a highly selective GPIIb/IIIa antagonist, demonstrated a prolonged duration of action after iv and po dosing and high affinity for resting and activated platelets. The prolonged antiplatelet profile of DMP 802 in dogs and the high affinity of DMP 802 for human platelets may be predictive of clinical utility as a once-daily antiplatelet agent. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
